Rincon Bio performs NCI-N87 xenograft models to test efficacy of preclinical therapies. Please see below for additional information or to request a quote.
NCI-N87 were derived from a patient with gastric cancer
Cells express the surface glycoproteins carcinoembryonic antigen (CEA) and TAG 72, and are L-dopa decarboxylase (DDC) negative. They were minimally positive for vasoactive intestinal peptide (VIP) receptors and lacked gastrin receptors. They were found to express receptors for muscarinic cholinergic agents. No evidence of amplification or rearrangements was noted with the N-myc, L-myc, myb and EGF receptor genes. The cell line expressed levels of c-myc and c-erb-B 2 RNA that were comparable to other cell lines.There was no expression of the following genes: N-myc, L-myc, c-cis, IGF-2, or gastrin releasing peptide. NCI-N87 cells have a reported plating efficiency of 4.3%. Ref
Used in xenografts to test the efficacy of novel cancer therapeutics. Tumors develop after being injected into the flank of immunocompromised mice.
Rincon Bio Growth Curves
NCI-N87 Trastuzumab Positive Control
Cell Line: NCI-N87
Mouse Strain: NOD.CB17 Prkd<Scid>/NCrHsd from Envigo
Positive Control: Trastuzumab
Cells Implanted per Animal: 5 million
From implant to stratification: 22 days
Stratification Size: 100mm^3
Dosing: Tail Vein, 4 times
Vehicle and Trastuzumab 20mg/kg dosed 4 times
NCI-N87 Kadcyla Positive Control
Positive Control: Kadcyla
Dosing: 4 doses, tail vein
From implant to stratification: 13 days
Cells Implanted: 5 million cells
WHY WORK WITH
When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices
Most efficacy studies can be initiated within two business days.
We love our clients! We are flexible and easy to work with. And we take a personal interest in our clients' studies.